Cryoablation can be considered for prostate cancer that has failed with external radiation therapy, and about 40% of patients have postoperative serum PSA levels that fall to undetectable levels. Also 78% of postoperative puncture biopsies are negative. If the PSA level drops to 0.5 ng/ml in patients after cryoablation, the average patient indicates a better prognosis. If the postoperative PSA is >0.5ng/ml, the patient may experience a re-rise in PSA or a positive biopsy. If the postoperative PSA is below 0.5 ng/ml in patients treated initially with cryoablation therapy, the prognosis is generally good. There is a correlation between postoperative complications of cryoablation therapy and the effectiveness of peripheral prostate tissue freezing, while transrectal ultrasound real-time monitoring and warm water circulation in the urethra are used during treatment to reduce the incidence of complications. Most patients with prostate cancer who fail radiotherapy are treated with cryoablation as a remedial treatment. Radiation therapy impairs the healing and repair and regenerative capacity of the tissues surrounding the prostate, thus increasing the occurrence of complications after cryoablation therapy. Common side effects of prostate cryoablation include pain in the perineal region, transient urinary retention, and hematuria. The incidence of urinary retention is about 3% and stress incontinence may be as high as 20%, while the overall incidence of incontinence is only 2%, but the incidence of incontinence after cryotherapy in patients who have failed radiotherapy is as high as 43%. The incidence of erectile dysfunction has been reported to be 40%, and urorectal fistulas are relatively rare.